A Ph 1 Study of Epanova® in Healthy Chineses

Study identifier:D5881C00001

ClinicalTrials.gov identifier:NCT03574142

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Epanova® in Chinese Healthy Subjects Living in China

Medical condition

Healthy subjects

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Epanova

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 04 Jun 2018

Primary Completion Date: 27 Jun 2018

Study Completion Date: 27 Jun 2018

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Feb 2019 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

:
1. Subjects must be willing and able to give written informed consent by signing an IRB-approved Informed Consent Form (ICF) prior to admission to this study and follow the restrictions and procedures outlined for the study.
2. Healthy adult males or females as determined by medical history, physical examination, and laboratory tests. Subjects are to be native Chinese, 18 to 45 years of age (inclusive) at the time of consent.
3. Body mass index (BMI) ≥19 and ≤26 kg/m2 and weigh at least 50 kg.
4. Medically healthy subjects with clinically insignificant screening results (eg, laboratory profiles, medical histories, electrocardiograms [ECGs], physical examination). Haemoglobin must be greater than the lower limit of normal. A 12-lead ECG with QTcF >340 msec and <450 msec.
5. Acceptable supine blood pressure (BP) and heart rate as determined by the investigator (systolic BP ≤140 mm Hg, and diastolic BP ≤90 mm Hg).
6. For women of childbearing potential (have not had tubal ligation, hysterectomy or surgical procedure for sterilisation), the results from a serum pregnancy test at screening and at Day -2 must be within the normal range. The subject must also agree to use an acceptable method of contraception throughout the trial. Women with an intact uterus are deemed postmenopausal if they are at least age 45, have had cessation of menses for at least 1 year, and have not taken hormones or oral contraceptives (including oestrogen or hormone replacement therapy) during the past 12 months.
Key

Exclusion Criteria

1. Past history of psychological or physical disorder.
2. An individual who has abnormal laboratory values or an inappropriate current or past medical history for participation based on the PI’s decision.
3. Has a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
4. Has a positive urine drug/alcohol breath testing at the screening visit or on Day -2.
5. Habitual users of drug(s) of abuse.
6. Has tested positive for human immunodeficiency virus (HIV), hepatitis B (including surface antigen [HbsAg] positive healthy carrier), hepatitis C antibodies (HCV), or syphilis.
7. Has used fish oil, other EPA and/or DHA containing supplements within 60 days of admission to the clinic.
8. Has a known sensitivity or allergy to soybeans, fish, and/or shellfish.
9. Has had a history of hypersensitivity or idiosyncratic reaction to compounds related to Epanova.
10. Pregnant or lactating women.
11. Those who have difficulty with blood sampling via a peripheral vein.

No locations available

Arms	Assigned Interventions
Experimental: Epanova Epanova® capsule, per oral	Drug: Epanova A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days. Other Name: Omega-3 carboxylic acids

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Yang Lin

Beijing Anzhen Hospital,Capital Medical University